Researchers at Columbia University report new clues about the earliest molecular events that may set Alzheimer's disease in motion, specifically how toxic tau filaments first begin to form in the brain. The work aims at a window well before significant memory loss and cognitive decline appear, which is where the team suggests future therapies could do the most good.
Tau is a protein that ordinarily helps hold neurons stable. In Alzheimer's, it becomes misshapen and clumps into the tangled filaments seen in patients' brains. Amyloid plaques have historically dominated the conversation about the disease, but a growing body of evidence points to tau pathology as the change that tracks most closely with worsening cognitive symptoms.
That distinction matters for drug development. The amyloid-clearing therapies approved in recent years have delivered only modest benefits, and many researchers now expect tau-directed approaches to have a better chance of slowing or preventing cognitive decline. Understanding what pushes normal tau into its misfolded, self-propagating form is a prerequisite for designing drugs that intervene at that step.
Progress here has been slow for a practical reason: tau does not misfold in animal models of Alzheimer's the way it does in people. To study tangles at all, researchers have had to take them from human brains after death and inject them into animals - a workaround that limits how well the earliest stages of the process can be observed. Any method that gets closer to how tau filaments actually begin in the human brain gives the field a firmer foundation for testing tau-targeted treatments.